Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639002 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00639002 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 13 participants.
The verdict
NCT00639002, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
Interventions
- DRUG Ruxolitinib 25 mg
- DRUG Dexamethasone 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639002
The ClinicalTrials.gov registry entry for NCT00639002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib 25 mg is the first listed.
NCT00639002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639002 about?
NCT00639002 is a clinical study titled "A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma". The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
What is the current status of trial NCT00639002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2008-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00639002?
The interventions under investigation include: Ruxolitinib 25 mg (DRUG), Dexamethasone 40 mg (DRUG).
Who is sponsoring clinical trial NCT00639002?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.